Gee i wonder if the xanadu prospect was reviewed by the directors - not a bad deal was on offer - buy into a target in Australia 160mmbbls, 40% cost for 25% - in the order of $3-4m well within GBP's better than peers cash in bank and expose shareholders to an interesting well.
probably not - that is at least a couple of years "administration"